Narcolepsy Market expected to rise by 2032 | Companies – Axsome Therapeutics, Inc., Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes

Narcolepsy Market expected to rise by 2032 | Companies - Axsome Therapeutics, Inc., Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes
Narcolepsy Market
DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Narcolepsy market growth is driven by factors like increase in the prevalence of Narcolepsy, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Narcolepsy market report also offers comprehensive insights into the Narcolepsy market size, share, Narcolepsy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Narcolepsy market size growth forward. 

Some of the key highlights from the Narcolepsy Market Insights Report:

  • Several key pharmaceutical companies, including Axsome Therapeutics, Inc., Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, Alkermes, KemPharm, and others, are developing novel products to improve the Narcolepsy treatment outlook. 
  • Promising therapies in the Narcolepsy market are AXS-12, SUVN-G3031, TAK-994, Mazindol, ADAIR, Research Programme: Orexin 2 Receptor Agonist, ONO-2909, HBS 102, XW10172, Ulotaront, HBS 102, ALKS 2680, KP 1077, and others.
  • The total Narcolepsy market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Narcolepsy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Narcolepsy Market Landscape

Narcolepsy Overview 

Narcolepsy is a rare, chronic neurological disorder characterized by sudden, uncontrollable episodes of sleep. Individuals with narcolepsy experience excessive daytime sleepiness, struggling to stay awake and concentrate throughout the day. They may also have sleep attacks, where they unexpectedly fall asleep without warning. Another symptom is cataplexy, a temporary loss of muscle control that leads to weakness or even collapsing. Cataplexy is often triggered by strong emotions such as laughter or anger. Additionally, people with narcolepsy may have vivid dreams and wake up frequently during the night, with dreams occurring as they fall asleep or upon waking.

The underlying cause of narcolepsy is often a deficiency in hypocretin, a brain chemical that regulates alertness. Due to its rarity and many cases going undiagnosed, the exact prevalence of narcolepsy is difficult to determine. Currently, there is no cure for narcolepsy, but lifestyle changes to improve sleep habits and medication can help minimize the impact of the condition on daily life.

Do you know the treatment paradigms for different countries? Download our Narcolepsy Market Sample Report

Narcolepsy Epidemiology Segmentation 

DelveInsight’s Narcolepsy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Narcolepsy historical patient pools and forecasted Narcolepsy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Narcolepsy Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Narcolepsy Prevalence 
  • Age-Specific Narcolepsy Prevalence 
  • Gender-Specific Narcolepsy Prevalence 
  • Diagnosed and Treatable Cases of Narcolepsy

Visit for more @ Narcolepsy Epidemiological Insights

Recent Breakthroughs in the Narcolepsy Market:

  • In June 2023, RareStone Group, a rare disease-focused company aiming to establish China’s first rare disease ecosystem, announced that pitolisant (Wakix) was approved by the Chinese National Medical Products Administration (NMPA) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult narcolepsy patients.
  • In July 2023, the FDA evaluated the full protocol of NLS Pharmaceutics’ NLS-1031 research, which is part of the AMAZE program investigating Mazindol ER as a therapy for narcolepsy.

Narcolepsy Treatment Market 

The Narcolepsy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Narcolepsy market trends by analyzing the impact of current Narcolepsy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Narcolepsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Narcolepsy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Narcolepsy market in 7MM is expected to witness a major change in the study period 2019-2032.

Narcolepsy Therapy Assessment

AXS-12: Axsome therapeutics

AXS-12 (reboxetine) is a norepinephrine reuptake inhibitor that is being developed for the treatment of narcolepsy. It increases wakefulness, maintains muscle tone, and improves cognition by modulating noradrenergic activity. Reboxetine has a long track record of safety in Europe and over 40 countries where it is licensed for the treatment of depression. Positive pre-clinical and Phase 2 clinical data in patients with narcolepsy show that AXS-12 improves daytime drowsiness while decreasing cataplexy (sudden loss of muscle control) in an open-label pilot experiment. AXS-12 has been designated as an Orphan Drug by the US Food and Drug Administration (FDA) for the treatment of narcolepsy. The medication is now being examined in the Phase III development stage.

Narcolepsy Key Companies

  • Axsome Therapeutics
  • Avadel Pharmaceuticals
  • Suven Life Sciences
  • Takeda
  • NLS Pharmaceutics
  • Vallon Pharmaceuticals
  • Alkermes
  • Centessa Pharmaceuticals
  • Ono Pharma
  • Harmony Biosciences
  • Reset Therapeutics
  • XWPharma
  • Sunovion Pharmaceuticals
  • Otsuka Pharmaceutical
  • ConSynance Therapeutics
  • Alkermes
  • KemPharm

Narcolepsy Therapies

  • AXS-12
  • SUVN-G3031
  • TAK-994
  • Mazindol
  • Research Programme
  • Orexin 2 Receptor Agonist
  • ONO-2909
  • HBS 102
  • XW10172
  • Ulotaront
  • HBS 102
  • ALKS 2680
  • KP 1077

For more information, visit Narcolepsy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Narcolepsy Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Narcolepsy, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Narcolepsy epidemiology in the 7MM
  • Narcolepsy marketed and emerging therapies 
  • Narcolepsy companies
  • Narcolepsy market drivers and barriers 

Key Questions Answered in the Narcolepsy Market Report 2032:

  • What was the Narcolepsy market share distribution in 2019, and how would it appear in 2032?
  • What is the total Narcolepsy market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Narcolepsy market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Narcolepsy market projected to expand at 7MM?

Table of Contents:

1 Narcolepsy Market Key Comprehensive Insights 

2 Narcolepsy Market Report Introduction

3 Competitive Intelligence Analysis for Narcolepsy

4 Narcolepsy Market Analysis Overview at a Glance

5 Executive Summary of Narcolepsy

6 Narcolepsy Epidemiology and Market Methodology

7 Narcolepsy Epidemiology and Patient Population

8 Narcolepsy Patient Journey

9 Narcolepsy Treatment Algorithm, Narcolepsy Current Treatment, and Medical Practices

10 Key Endpoints in Narcolepsy Clinical Trials

11 Narcolepsy Marketed Therapies 

12 Narcolepsy Emerging Therapies

13 Narcolepsy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Narcolepsy

16 Narcolepsy Market Key Opinion Leaders Reviews

18 Narcolepsy Market Drivers

19 Narcolepsy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Narcolepsy Epidemiology 2032

DelveInsight’s “Narcolepsy – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Narcolepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Narcolepsy Pipeline 2023

“Narcolepsy Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Narcolepsy market. A detailed picture of the Narcolepsy pipeline landscape is provided, which includes the disease overview and Narcolepsy treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States